Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 22, 2020
The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development networkKelsie Pearson, Nicole Mayer-Hamblett, Christopher H Goss, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 19, 2021
Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infectionDiana Bilton, Isabelle Fajac, Tacjana Pressler, et al.JMIR Medical Informatics|December 16, 2020
Cystic Fibrosis Point of Personalized Detection (CFPOPD): An Interactive Web ApplicationChristopher Wolfe, Teresa Pestian, Emrah Gecili, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 28, 2019
Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosisDiana Bilton, Tacjana Pressler, Isabelle Fajac, et al.The Lancet. Respiratory Medicine|September 12, 2023
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapyKatherine B Hisert, Susan E Birket, John Paul Clancy, et al.Chest|May 18, 2010
An international randomized multicenter comparison of nasal potential difference techniquesGeorge M Solomon, Michael W Konstan, Michael Wilschanski, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 25, 2014
Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial dataFrank J Accurso, Fredrick Van Goor, Jiuhong Zha, et al.American Journal of Physiology. Lung Cellular and Molecular Physiology|March 12, 2020
Neutrophil extracellular traps activate IL-8 and IL-1 expression in human bronchial epitheliaKristin M Hudock, Margaret S Collins, Michelle Imbrogno, et al.The Lancet. Respiratory Medicine|November 7, 2022
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsNicole Mayer-Hamblett, Felix Ratjen, Renee Russell, et al.The Lancet. Respiratory Medicine|September 12, 2023
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspectiveNicole Mayer-Hamblett, John Paul Clancy, Raksha Jain, et al.Pageof 3